The cost‐utility and budget impact analyses of Tirzepatide versus once‐weekly Semaglutide as add‐on therapy to metformin in patients with type 2 diabetes mellitus in China
Authors' conclusion
This dual analysis provides policymakers and payers with a comprehensive basis for decision-making. Tirzepatide offered substantial long-term health benefits, but they were not cost-effective compared with semaglutide 1 mg in T2DM patients inadequately controlled with metformin under China's health care providers' perspective. The entry of tirzepatide 5 mg into the NHIS may increase the financial burden of national medical insurance, but overall health care expenditures are expected to decrease, driven primarily by significantly reduced out-of-pocket expenses for patients.
Study context
- Population
- Simulated patients with T2D inadequately controlled with metformin, China (SURPASS-2 data)
- Exposure
- Tirzepatide 5 mg and 10 mg vs semaglutide 1 mg, add-on to metformin
- Outcome
- Incremental cost-utility ratio (costs and QALYs)
- Follow-up
- Long-term
Methodological detailsUK Prospective Diabetes Study Outcomes Model Version 2.2, Chinese health care providers' perspective, efficacy data from SURPASS-2 trial, sensitivity analyses, 5-year budget impact
- UK Prospective Diabetes Study Outcomes Model Version 2.2
- Chinese health care providers' perspective
- Efficacy data from SURPASS-2 trial
- Sensitivity analyses
- 5-year budget impact
Main finding
As reported in the abstract
Incremental quality-adjusted life years (QALYs)
0.05 QALYs
Tirzepatide 5 mg · incremental cost $23 563.42; ICUR $445 125.24/QALY
Incremental QALYs
0.09 QALYs
Tirzepatide 10 mg · incremental cost $47 583.74; ICUR $543 829.19/QALY
- Willingness-to-pay threshold (both ICURs exceeded it)
- $29 599.90/QALY
Observational data: associations, not effects.
Further findings
Budget impact for national health insurance system (NHIS) · 5 years
- Additional budgetary burden
- approximately $80 million to $490 million
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →